As expected, T2D patients treated with metformin displayed significant differences in glucose metabolism parameters, including elevated levels of glucose (p < 0.001), insulin (p < 0.05), HOMA-IR (p < 0.01) and HbA1c (p < 0.001) with respect to the MHO group. The gene discussed is INS; the disease is type 2 diabetes mellitus.